This is likely due to their ability to enhance NK-mediated ADCC and consequently could be investigated in combination with monoclonal antibodies or ADCs such as mogamulizumab (anti-CCR4) and brentuximab vedotin (anti-CD30) in r/r PTCL patients. This evidence concerns the gene CCR4 and mature T-cell and NK-cell non-Hodgkin lymphoma.